Overexpression of RhoGDI2 protein correlates with tumor invasion and metastasis in colorectal cancer

doi:10.3877/cma.j.issn.2095-3224.2016.04.010

Abstract

Abstract:

Objective

To detect the expression of Rho GDP dissociation inhibitor 2 (RhoGDI2) and analyze the function of RhoGDI2 in the colorectal cancer. To discuss the role of RhoGDI2 in the developmetal process of colorectal cancer.

Methods

Immunohistochemistry was used to detect RhoGDI2 protein in 153 cases of colorectal cancer and adjacent tissue specimens.

Results

Specimens from 153 cases of colorectal cancer were selected from Affiliated Hospital of Shandong Academy of Medical Sciences between July 2012 and July 2014. RhoGDI2 was expressed mainly in colorectal cancer, mainly in the cytoplasm. The positive rate of RhoGDI2 protien expression was significantly higher in cancer tissue than in normal colorectal tissue (57.5 % vs 0.00%). RhoGDI2 expression in colorectal cancer tissue with the low differentiation group was significantly higher than in the high and moderate differentiation group. The expression of RhoGDI2 protein in colorectal cancer was significantly correlated with tumor size (χ²=4.293, P<0.05), grade of differentiation (χ²=2.090, P<0.05), depth of invasion (χ²=1.711, P<0.05), lymph node metastasis (χ²=5.925, P<0.05), distant metastasis (χ²=5.519, P<0.05), and clinical stage (χ²=5.683, P<0.05). RhoGDI2 expression in colorectal cancer was no correlated with gender (χ²=0.037, P>0.05)、age (<60 years vs≥60 years) (χ²=0.054, P>0.05).

Conclusions

RhoGDI2 expression was positively correlated with the invasion and metastasis of colorectal cancer, and RhoGDI2 may play an important role in the occurrence and development of colorectal cancer.

Key words: Colorectal neoplasms, Neoplasm metastasis, Invasion, RhoGDI2

Shoutang Lu, Suifang Wu, Meiling Jin, Qilong Wang, Yanan Zhen, Huiyong Shi, Chengjun Li, Zhongfa Xu. Overexpression of RhoGDI2 protein correlates with tumor invasion and metastasis in colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(04): 328-332.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2016.04.010

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2016/V05/I04/328

Figures/Tables 2

References 12

[1]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA: a cancer journal for clinicians, 2016, 66(2):115-132.
[2]	Takanori Ochiai, Taiki Masuda, Masayuki Yagi, et al. Successful combination therapy of radical liver resection with 5-Fluorouracil/leucovorin, oxaliplatin, plus bevacizumab for ascending colon cancer with pulmonary and 43 liver metastases: report of a case[J].International Surgery, 2012, 97(1):6-13.
[3]	Nobes CD, Hall A. Rho, rac and cdc42 GTPase:regulators of actin structures,cell adhesion and motility[J]. Biochem Soc Trans, 1995, 23(3):456-459.
[4]	Aznar S, Lacal JC. Rho signals to ell growth and apoptosis[J]. Cancer Lett, 2001, 165(1):1-10.
[5]	Dovas A, Couchman JR. RhoGDI: multiple functions in the regulation of family GTPase activities[J]. Biochem J, 2005, 390(Pt1):1-9.
[6]	Seraj MJ, Harding MA, Gildea JJ, et al. The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential inlineage related human bladder cancer cell lines[J]. Clin Exp Metastasis, 2000, 18(6):519-525.
[7]	Theodorescu D, Sapinoso LM, Conaway MR, et al. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer[J]. Clin Cancer Res, 2004, 10(11):3800-3806.
[8]	Huiyan N, Hui L, Can X, et al. Expression profile of RhoGDI2 in lung cancers and role of RhoGDI2 in lung cancer metastasis[J]. Oncology Reports, 2010, 24(2):465-471.
[9]	Liya M, Gaixiang X, Anna S, et al. Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma[J]. British Journal of Haematology, 2007, 139(2):217-223.
[10]	鲁守堂，杨建树，李成军,等. RhoGDI2蛋白的高表达促进胃癌的侵袭和转移[J].世界华人消化杂志, 2015(13):2064-2070.
[11]	Hee Jun C, Kyoung Eun B, Sun-Mi P, et al. RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer[J]. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2009, 15(8):2612-2619.
[12]	Bsc X L, Bsc J W, Zhang X, et al. Overexpression of RhoGDI2 correlates with tumor progression and poor prognosis in colorectal carcinoma[J]. Annals of Surgical Oncology, 2012, 19(1):145-153.

临床病理特点		例数	RhoGDI2表达		χ²值	P值
临床病理特点		例数	阳性	阴性
性别（例）		?	?	?	0.037	0.847
?	男	81	46	35	?	?
?	女	72	42	30	?	?
年龄（岁）		?	?	?	0.054	0.816
?	<60	77	45	32	?	?
?	≥60	76	43	33	?	?
原发灶直径（cm）		?	?	?	4.293	0.038
?	<5	63	30	33	?	?
?	≥5	90	58	32	?	?
组织学分级（例）		?	?	?	2.090	0.148
?	高-中分化	91	48	43	?	?
?	低分化	62	40	22	?	?
原发灶浸润深度（例）		?	?	?	1.711	0.191
?	T1-2	66	34	32	?	?
?	T3-4	87	54	33	?	?
淋巴结转移（例）		?	?	?	5.925	0.015
?	N0	79	38	41	?	?
?	N1-3	74	50	24	?	?
远处转移（例）		?	?	?	5.519	0.019
?	M0	82	40	42	?	?
?	M1	71	48	23	?	?
临床分期（例）		?	?	?	5.683	0.017
?	Ⅰ～Ⅱ期	70	33	37	?	?
?	Ⅲ～Ⅳ期	83	55	28	?	?

临床病理特点		例数	RhoGDI2表达		χ²值	P值
临床病理特点		例数	阳性	阴性
性别（例）		?	?	?	0.037	0.847
?	男	81	46	35	?	?
?	女	72	42	30	?	?
年龄（岁）		?	?	?	0.054	0.816
?	<60	77	45	32	?	?
?	≥60	76	43	33	?	?
原发灶直径（cm）		?	?	?	4.293	0.038
?	<5	63	30	33	?	?
?	≥5	90	58	32	?	?
组织学分级（例）		?	?	?	2.090	0.148
?	高-中分化	91	48	43	?	?
?	低分化	62	40	22	?	?
原发灶浸润深度（例）		?	?	?	1.711	0.191
?	T1-2	66	34	32	?	?
?	T3-4	87	54	33	?	?
淋巴结转移（例）		?	?	?	5.925	0.015
?	N0	79	38	41	?	?
?	N1-3	74	50	24	?	?
远处转移（例）		?	?	?	5.519	0.019
?	M0	82	40	42	?	?
?	M1	71	48	23	?	?
临床分期（例）		?	?	?	5.683	0.017
?	Ⅰ～Ⅱ期	70	33	37	?	?
?	Ⅲ～Ⅳ期	83	55	28	?	?

[1]	Miao Li, Lianhua Zhu, Peng Han, Bo Jiang, Xiang Fei. Evaluation of relationsip between vascular morphology and risk factors for hepatocellular carcinoma by high-frame-rate contrast-enhanced ultrasound [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(09): 911-915.
[2]	Xia Kang, Hao Tian, Jin Qian, Yuan Gao, Hongming Miao, Xiaowei Qi. Osteorin attenuates osteolysis during bone metastasis of cancers through inhibiting osteoclastogenesis [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 329-339.
[3]	Dechen Wang, Kang Yang, Zijie Yang, Mingbin Gui, Lianping Qu, Xiaofeng Zhang, Feng Gao. Progress of microsatellite stability state and PD-1/PD-L1/IDO in colorectal carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 462-465.
[4]	Xiongxiong Li, Chan Zhou, Ting Xu, Yu Ren, Jin Shang. Metastasis rate of newly diagnosed ductal carcinoma in situ with microinvasive axillary lymph nodes: A Meta-analysis [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 466-474.
[5]	Xu Tang, Bing Han, Wei Liu, Ruxing Chen. Analysis of risk factors for metachronous liver metastases after radical colorectal cancer surgery and construction of a predictive model [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 16-20.
[6]	Shengjun Zhang, Ajing Zhao, Shoubo Li, Xianghong Hao, Minli Liu. An experimental study on the promotion of colorectal cancer invasion and migration by high glucose through HGF/c-met pathway [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 21-24.
[7]	Qingyan Yan, Xiaomei Yong, Hong Luo, Min Du. Prognostic factors and survival analysis of multicenter elderly patients with metastatic breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 636-638.
[8]	Ting Li, Lin Zhang. Relationship between serum fatty acid metabolites and vitamin D levels and colorectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 661-665.
[9]	Jian Chang, Feng Qiu, Yuqi Mao. Analysis of the relationship between ingestion inhibition factor-1 and liver metastasis after laparoscopic radical resection of colorectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(05): 502-505.
[10]	Qing Yan, Ying Liu, Feiwen Deng, Huanwei Chen. Effect of microvascular invasion on survival and prognosis of liver transplantation recipients with liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 624-629.
[11]	Xu Guan, Xishan Wang. Reflecting on the merits and demerits of regional lymph node management in colorectal cancer based on surgical and immune perspectives [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 448-452.
[12]	Ruiqi Gu, Hongsheng Fang, Guoxiang Cai. Application and progress of circulating tumor DNA detection technology in the diagnosis and treatment of colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 453-459.
[13]	Wenkai Ni, Chong Qi, Xiaodan Xu, Xiecheng Zhou, Qingzhang Yin, Yuankun Cai. Analysis of influencing factors of prolonged postoperative ileus in patients with colorectal cancer after operation [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 484-489.
[14]	Xiaoyu Fan, Sizheng Sun, Yimin E, Chunzhao Yu. Different surgical options for obstructive left colon cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 500-504.
[15]	Bing Lan, Huaiming Wang, Hui Wang, Bo Ma. Research progress on locally advanced colon cancer with bladder invasion [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 505-511.

Please choose a citation manager

Content to export